These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36057843)

  • 21. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
    Chen H; Cheng Q; Wang J; Zhao X; Zhu S
    J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease.
    Hasegawa S; Tanaka T; Saito T; Fukui K; Wakashima T; Susaki EA; Ueda HR; Nangaku M
    Kidney Int; 2020 May; 97(5):934-950. PubMed ID: 32171449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
    Sugahara M; Tanaka T; Nangaku M
    Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
    Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A
    Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the Phosphate Binder Sevelamer Carbonate on the Bioavailability of Enarodustat, an Oral Erythropoiesis Stimulating Agent.
    Pai SM; Yamada H
    Clin Pharmacol Drug Dev; 2024 Jan; 13(1):111-116. PubMed ID: 37975611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A
    Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study.
    Parmar DV; Kansagra KA; Patel JC; Joshi SN; Sharma NS; Shelat AD; Patel NB; Nakrani VB; Shaikh FA; Patel HV;
    Am J Nephrol; 2019; 49(6):470-478. PubMed ID: 31112954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The comparison of four hypoxia-inducible factor prolyl hydroxylase inhibitors on drug potency and cost for treatment in patients with renal anemia.
    Imai E; Imai A
    Clin Exp Nephrol; 2024 Nov; 28(11):1090-1096. PubMed ID: 38767688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
    Akizawa T; Ueno M; Shiga T; Reusch M
    Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.
    Uchida L; Tanaka T; Saito H; Sugahara M; Wakashima T; Fukui K; Nangaku M
    Am J Physiol Renal Physiol; 2020 Feb; 318(2):F388-F401. PubMed ID: 31841388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
    Akizawa T; Iwasaki M; Otsuka T; Reusch M; Misumi T
    Adv Ther; 2019 Jun; 36(6):1438-1454. PubMed ID: 30953333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of Enarodustat in Non-Japanese and Japanese Healthy Subjects and in Patients With End-Stage Renal Disease on Hemodialysis.
    Pai SM; Kambhampati SRP; Naruhashi S; Yamada H
    Clin Pharmacol Drug Dev; 2023 Jul; 12(7):683-690. PubMed ID: 37203396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
    Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M
    J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
    Akizawa T; Otsuka T; Reusch M; Ueno M
    Ther Apher Dial; 2020 Apr; 24(2):115-125. PubMed ID: 31222951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis.
    Zhang S; Guo J; Xie S; Chen J; Yu S; Yu Y
    Int Urol Nephrol; 2021 Jun; 53(6):1139-1147. PubMed ID: 33026571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents.
    Nangaku M; Kondo K; Takabe S; Ueta K; Tandai T; Kawaguchi Y; Komatsu Y
    Ther Apher Dial; 2022 Feb; 26(1):45-54. PubMed ID: 34115437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Mass Balance Study of
    Pai SM; Connaire J; Yamada H; Enya S; Gerhardt B; Maekawa M; Tanaka H; Koretomo R; Ishikawa T
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):728-741. PubMed ID: 31876104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
    Martin ER; Smith MT; Maroni BJ; Zuraw QC; deGoma EM
    Am J Nephrol; 2017; 45(5):380-388. PubMed ID: 28343225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypoxia inducible factor-prolyl hydroxylase inhibitors in anemic patients with non-dialysis dependent chronic kidney disease: a meta-analysis of randomized clinical trials.
    Mohamed MMG; Oyenuga M; Shaikh S; Oyenuga A; Kheiri B; Nwankwo C
    Int Urol Nephrol; 2023 Jan; 55(1):167-171. PubMed ID: 35852713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
    Maruno S; Tanaka T; Nangaku M
    Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.